Sometimes when something doesn’t make sense you can either scratch your head or take a closer to look to see if you perhaps missed something. We mention this as we just couldn’t understand why Novo Nordisk was studying the oral version of semaglutide to death. Why they weren’t aggressively getting this drug to the FDA.
At first, we chalked up this lackadaisical attitude to Novo being Novo. A company that based on their history has never meet a study they didn’t like. With the GLP-1 market continuing to grow and this being a potential blockbuster . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.